Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 32,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo/Control Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vyvanse in Children Aged 6 to 12 Years

NCT05416125
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Lisdexamfetamine Dimesylate, Lifestyle therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 19, 2026, 11:04 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Selenium Intervention on Inflammation in Older Adults

NCT01289925
View directory record Official record
Conditions
Inflammation
Interventions
Selenium, Sugar Pill Placebo
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years to 110 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 19, 2026, 11:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Brief Stresses Experimental Study

NCT03893617
View directory record Official record
Conditions
DNA Damage, Psychological Stress
Interventions
Propranolol, Placebo oral capsule, Acute stress task, No stress task
Drug · Behavioral
Lead sponsor
Dana Bovbjerg
Other
Eligibility
20 Years to 59 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Not applicable Interventional Results available

VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents

NCT03065517
View directory record Official record
Conditions
Child Behavior Disorders
Interventions
VillageWhere App, Attention-Control Placebo App
Device
Lead sponsor
Evidence-Based Practice Institute, Seattle, WA
Industry
Eligibility
13 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 19, 2026, 11:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 2 Interventional Results available

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NCT03452189
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy

NCT05121168
View directory record Official record
Conditions
Pain, Acute Postoperative, Renal Stone
Interventions
Active bupivacaine 0.25% via an erector spinae plane perineural catheter, Placebo normal saline via an erector spinae plane perineural catheter
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 11:04 PM EDT
Recruiting Not applicable Interventional

Myo-inositol During Pregnancy to Prevent Gestational Diabetes

NCT06575868
View directory record Official record
Conditions
Pregnancy Related
Interventions
Myo-inositol, Myo-inositol placebo
Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
QBW251, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 11:04 PM EDT
Recruiting Phase 4 Interventional

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

NCT06829238
View directory record Official record
Conditions
Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions
Metformin, Placebo, Jynneos, Capvaxvie
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT00051558
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 3 Interventional Results available

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
368
States / cities
Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Provoked Craving Assessment

NCT01506908
View directory record Official record
Conditions
Smoking Dependence, Smoking
Interventions
oral nicotine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

NCT05161208
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 1 Interventional

Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream

NCT00690625
View directory record Official record
Conditions
Myofacial Pain
Interventions
MyoRx Cream (6% Omega 3 Fatty Acid), Placebo cream, no Omega 3 fatty acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2008 · Synced Oct 19, 2026, 11:04 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717
View directory record Official record
Conditions
Allergic Rhinitis Due to Cat Allergy
Interventions
REGN1908-1909, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 19, 2026, 11:04 PM EDT
Not listed Phase 4 Interventional

An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization

NCT04729140
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Tablets, Doxycycline Tablets, Placebo
Drug
Lead sponsor
Max Health, Subsero Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures

NCT01277640
View directory record Official record
Conditions
Topical Penile Exposures
Interventions
dapivirine, matched placebo, universal placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 19, 2026, 11:04 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 11:04 PM EDT
Terminated Phase 2 Interventional Results available

Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers

NCT02863068
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Topical Sodium Nitrite, Placebo
Drug · Other
Lead sponsor
caterina P minniti
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
The Bronx, New York • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 11:04 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Interaction Between TMP-301 and Cocaine.

NCT06648668
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
TMP-301, Placebo
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 19, 2026, 11:04 PM EDT